308 related articles for article (PubMed ID: 24496001)
21. Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.
Higgs JT; Jarboe JS; Lee JH; Chanda D; Lee CM; Deivanayagam C; Ponnazhagan S
Mol Cancer Res; 2015 May; 13(5):819-27. PubMed ID: 25636966
[TBL] [Abstract][Full Text] [Related]
22. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
23. Tricetin, a dietary flavonoid, suppresses benzo(a)pyrene‑induced human non‑small cell lung cancer bone metastasis.
Hung JY; Chang WA; Tsai YM; Hsu YL; Chiang HH; Chou SH; Huang MS; Kuo PL
Int J Oncol; 2015 May; 46(5):1985-93. PubMed ID: 25738754
[TBL] [Abstract][Full Text] [Related]
24. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
25. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis.
Chanda D; Isayeva T; Kumar S; Siegal GP; Szafran AA; Zinn KR; Reddy VV; Ponnazhagan S
Mol Ther; 2008 May; 16(5):871-8. PubMed ID: 18388919
[TBL] [Abstract][Full Text] [Related]
26. Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.
Fisher JL; Thomas-Mudge RJ; Elliott J; Hards DK; Sims NA; Slavin J; Martin TJ; Gillespie MT
Cancer Res; 2006 Apr; 66(7):3620-8. PubMed ID: 16585187
[TBL] [Abstract][Full Text] [Related]
27. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.
Zinonos I; Luo KW; Labrinidis A; Liapis V; Hay S; Panagopoulos V; Denichilo M; Ko CH; Yue GG; Lau CB; Ingman W; Ponomarev V; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Int J Oncol; 2014 Aug; 45(2):532-40. PubMed ID: 24865346
[TBL] [Abstract][Full Text] [Related]
30. Osteoprotegerin in bone metastases: mathematical solution to the puzzle.
Ryser MD; Qu Y; Komarova SV
PLoS Comput Biol; 2012; 8(10):e1002703. PubMed ID: 23093918
[TBL] [Abstract][Full Text] [Related]
31. The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review).
Jimi E; Shin M; Furuta H; Tada Y; Kusukawa J
Int J Oncol; 2013 Mar; 42(3):803-9. PubMed ID: 23354319
[TBL] [Abstract][Full Text] [Related]
32. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases.
Terpos E; Efstathiou E; Christoulas D; Roussou M; Katodritou E; Dimopoulos MA
Expert Opin Biol Ther; 2009 Apr; 9(4):465-79. PubMed ID: 19344283
[TBL] [Abstract][Full Text] [Related]
33. Characterization of neuroblastoma bone invasion/metastasis in established bone metastatic model of SY5Y and KCNR cell lines.
Zhao H; Cai W; Li S; Da Z; Sun H; Ma L; Lin Y; Zhi D
Childs Nerv Syst; 2013 Jul; 29(7):1097-105. PubMed ID: 23559392
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.
Lamoureux F; Richard P; Wittrant Y; Battaglia S; Pilet P; Trichet V; Blanchard F; Gouin F; Pitard B; Heymann D; Redini F
Cancer Res; 2007 Aug; 67(15):7308-18. PubMed ID: 17671200
[TBL] [Abstract][Full Text] [Related]
35. Exploration of the Effect of Icariin on Nude Mice with Lung Cancer Bone Metastasis via the OPG/RANKL/RANK System.
Ruilian Z; Ying G; Hongmei S; Lihua G
Comput Math Methods Med; 2022; 2022():2011625. PubMed ID: 35669373
[TBL] [Abstract][Full Text] [Related]
36. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
37. [Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor].
Kushlinskiĭ NE; Timofeev IuS; Gershteĭn ES; Solov'ev IuN
Vopr Onkol; 2014; 60(4):413-21. PubMed ID: 25552059
[TBL] [Abstract][Full Text] [Related]
38. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
39. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
Roodman GD; Dougall WC
Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
[TBL] [Abstract][Full Text] [Related]
40. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
